{"id":"mmr-vaccination","safety":{"commonSideEffects":[{"rate":"10–20","effect":"Injection site pain, redness, or swelling"},{"rate":"5–15","effect":"Fever"},{"rate":"5","effect":"Rash"},{"rate":"<1","effect":"Parotitis (mumps-like symptoms)"},{"rate":"1–3","effect":"Arthralgia or arthritis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in vaccinated individuals but do not cause disease. This triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protective immunity against these three viral infections. Upon exposure to wild-type virus, the primed immune system rapidly produces neutralizing antibodies and activates T cells to prevent infection or severe disease.","oneSentence":"MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:40.668Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles"},{"name":"Prevention of mumps"},{"name":"Prevention of rubella"}]},"trialDetails":[{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT06074237","phase":"NA","title":"Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters","status":"COMPLETED","sponsor":"Corewell Health East","startDate":"2024-04-25","conditions":"Vaccine Refusal, Vaccine-Preventable Diseases, Physician-Patient Relations","enrollment":112},{"nctId":"NCT06442449","phase":"PHASE4","title":"Booster Dose of sIPV Co-administered With MMR and HepA-I.","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2024-08-08","conditions":"Poliomyelitis","enrollment":889},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT06411691","phase":"PHASE1","title":"KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-06-24","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":54},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT04117087","phase":"PHASE1","title":"Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-05-28","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":27},{"nctId":"NCT07195032","phase":"PHASE4","title":"Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients","status":"RECRUITING","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2025-09-11","conditions":"Heart Transplant Infection Prevention","enrollment":60},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06456788","phase":"","title":"Barriers and Facilitators to MMR Vaccination Among Healthcare Workers","status":"COMPLETED","sponsor":"King's College London","startDate":"2024-09-12","conditions":"Measles","enrollment":23},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT01885702","phase":"PHASE1, PHASE2","title":"Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2010-10","conditions":"Colorectal Cancer","enrollment":25},{"nctId":"NCT06218368","phase":"NA","title":"A Tool Kit to Improve Vaccine Confidence in the Philippines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Toronto","startDate":"2024-01-31","conditions":"Measles, Polio, Vaccination Hesitancy","enrollment":5400},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT04475081","phase":"PHASE3","title":"Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2020-09-22","conditions":"Sepsis Syndrome","enrollment":50},{"nctId":"NCT04567342","phase":"NA","title":"Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2020-11-27","conditions":"Preventable Disease, Vaccine, Health Care Utilization","enrollment":1312},{"nctId":"NCT05758532","phase":"PHASE4","title":"Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children","status":"RECRUITING","sponsor":"Laure Pittet, MD-PhD","startDate":"2023-03-17","conditions":"Respiratory Tract Infections, Infections, Allergy","enrollment":500},{"nctId":"NCT06361628","phase":"NA","title":"Implementation and Evaluation of Tailored Interventions to Increase MMR and/or HPV Vaccine","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-05-01","conditions":"Vaccination, Health Systems, Knowledge, Attitudes, Practice","enrollment":1000},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT06312228","phase":"NA","title":"The Effect of the Helper Skin Tap Technique and Buzzy® During Vaccination","status":"COMPLETED","sponsor":"Tarsus University","startDate":"2023-05-01","conditions":"Child, Only","enrollment":96},{"nctId":"NCT05894395","phase":"PHASE3","title":"Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2023-12-01","conditions":"Mumps, Measles, Rubella","enrollment":200},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT05166044","phase":"","title":"Safety Observation of Enterovirus 71 Inactivated Vaccine (Vero Cell) Combined Immunization in Shanghai","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-01-04","conditions":"Hand, Foot and Mouth Disease","enrollment":12500},{"nctId":"NCT05279248","phase":"PHASE4","title":"The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-08-25","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles","enrollment":300},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT04646239","phase":"","title":"Biomarkers of Trained Immunity Following MMR Vaccination","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-12-17","conditions":"Covid19","enrollment":96},{"nctId":"NCT00013871","phase":"NA","title":"Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Measles","enrollment":300},{"nctId":"NCT00257127","phase":"NA","title":"Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":101},{"nctId":"NCT02861586","phase":"PHASE2","title":"Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2016-08-17","conditions":"Chikungunya Virus Infection","enrollment":263},{"nctId":"NCT00000815","phase":"PHASE2","title":"A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Measles","enrollment":270},{"nctId":"NCT00962819","phase":"","title":"Measles, Mumps, and Rubella (MMR) Immunity in College Students","status":"COMPLETED","sponsor":"Sri Edupuganti, MD MPH","startDate":"2010-03","conditions":"Measles, Mumps, Rubella","enrollment":74},{"nctId":"NCT04998838","phase":"NA","title":"Stop Hep B @ Birth","status":"UNKNOWN","sponsor":"Myanmar Liver Foundation","startDate":"2018-07-01","conditions":"Hepatitis B","enrollment":110},{"nctId":"NCT04990648","phase":"NA","title":"Buzzy® Application in Pain","status":"COMPLETED","sponsor":"Okan University","startDate":"2018-11-15","conditions":"Healthy","enrollment":60},{"nctId":"NCT04111432","phase":"PHASE4","title":"Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-26","conditions":"Hand, Foot and Mouth Disease","enrollment":372},{"nctId":"NCT04638985","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-13","conditions":"Vaccine","enrollment":600},{"nctId":"NCT02880865","phase":"PHASE4","title":"Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2016-10-13","conditions":"Encephalitis, Japanese, Measles, Mumps","enrollment":628},{"nctId":"NCT01770119","phase":"PHASE4","title":"Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Klara M. Pósfay Barbe","startDate":"2013-04","conditions":"Measles","enrollment":90},{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT00892775","phase":"PHASE2","title":"Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Measles, Varicella, Mumps","enrollment":501},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00326118","phase":"PHASE3","title":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":433},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00871117","phase":"PHASE3","title":"Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-31","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":478},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450},{"nctId":"NCT00871000","phase":"PHASE3","title":"Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":303},{"nctId":"NCT02325310","phase":"PHASE4","title":"Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02-04","conditions":"Measles, Rubella, Mumps","enrollment":14},{"nctId":"NCT02253407","phase":"PHASE4","title":"Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2014-09","conditions":"Immune Response to MMR Vaccine","enrollment":341},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT03160820","phase":"PHASE4","title":"Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2016-03","conditions":"Measles, Mumps, Rubella","enrollment":873},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT02724852","phase":"PHASE4","title":"MMR Vaccination Among HIV-infected Adults","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2011-07","conditions":"HIV","enrollment":632},{"nctId":"NCT02712203","phase":"","title":"MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2004-07","conditions":"Measles","enrollment":5808},{"nctId":"NCT00381615","phase":"PHASE2","title":"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Healthy","enrollment":147},{"nctId":"NCT00156559","phase":"","title":"MMR and Varicella Vaccine in Premature Infants","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2004-01","conditions":"Chickenpox, Rubella, Rubeola","enrollment":32},{"nctId":"NCT02432430","phase":"NA","title":"Comparison of Immunization Quality Improvement Dissemination Study","status":"COMPLETED","sponsor":"Children's National Research Institute","startDate":"2013-06","conditions":"Immunization, DTaP Vaccine, Hepatitis B Vaccine","enrollment":2186},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT00731965","phase":"PHASE4","title":"Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"N.M. Wulffraat","startDate":"2008-05","conditions":"Arthritis, Juvenile Rheumatoid","enrollment":140},{"nctId":"NCT01199666","phase":"NA","title":"Text Message Reminder-Recalls For Early Childhood Vaccination","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-06","conditions":"Vaccination","enrollment":2586},{"nctId":"NCT02146469","phase":"PHASE4","title":"Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2012-12","conditions":"Varicella","enrollment":1200},{"nctId":"NCT01000311","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-11","conditions":"Meningococcal Disease","enrollment":529},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT01544764","phase":"NA","title":"Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-04","conditions":"Adolescent Health Services, Immunization","enrollment":91},{"nctId":"NCT00806195","phase":"PHASE3","title":"Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-12","conditions":"Meningitis, Meningococcal Infection","enrollment":7744},{"nctId":"NCT00258726","phase":"PHASE1, PHASE2","title":"Immune Responses to Two Dose Varivax +/- MMR-II","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Measles, Mumps, Rubella","enrollment":105}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BLOOD CREATINE PHOSPHOKINASE INCREASED"},{"count":1,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DEPRESSED LEVEL OF CONSCIOUSNESS"},{"count":1,"reaction":"GENERALISED TONIC-CLONIC SEIZURE"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"HISTOPLASMOSIS DISSEMINATED"},{"count":1,"reaction":"JAUNDICE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MMR vaccination","genericName":"MMR vaccination","companyName":"Klara M. Pósfay Barbe","companyId":"klara-m-p-sfay-barbe","modality":"Biologic","firstApprovalDate":"","aiSummary":"MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}